Meta Information
ID:tesamorelin
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
1
Description:
Elevated blood glucose and insulin from a recent meal can suppress the pituitary gland's response to Tesamorelin, significantly blunting the resulting growth hormone (GH) release.
Actionable advice:
Administer on an empty stomach, at least 2 hours after your last meal and 1 hour before your next.
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
null
Description:
Tesamorelin stimulates the pituitary to release growth hormone (GH), and administering it before sleep mimics the body's largest natural GH pulse, which occurs during deep sleep.
Actionable advice:
Inject subcutaneously approximately 30 minutes before you go to bed for optimal effect.
Target id:
/condition/active-malignancy
Target name:
Active Malignancy (Cancer)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Tesamorelin increases levels of IGF-1, a potent growth factor that could potentially accelerate the growth of existing tumors. It is contraindicated in patients with active cancer.
Actionable advice:
Do not use if you have any active cancer.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
The effects of Tesamorelin on fetal development are unknown and could be harmful. It is contraindicated during pregnancy.
Actionable advice:
Avoid completely if you are pregnant or planning to become pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
It is not known if Tesamorelin passes into breast milk, and its effects on a nursing infant are unknown, making it contraindicated.
Actionable advice:
Do not use while breastfeeding.
Target id:
/condition/acute-critical-illness
Target name:
Acute Critical Illness
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
High doses of growth hormone have been associated with increased mortality in critically ill patients (e.g., after major surgery, trauma, or respiratory failure). Tesamorelin should be discontinued in this setting.
Actionable advice:
Discontinue use immediately if you develop an acute critical illness.
Target id:
/condition/diabetes-mellitus
Target name:
Diabetes Mellitus
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Tesamorelin can increase the risk of new-onset diabetes and worsen glycemic control in existing diabetics by causing insulin resistance.
Actionable advice:
Use with extreme caution and under strict medical supervision, as it may worsen blood sugar control.
Target id:
/class/somatostatin-analogs
Target name:
Somatostatin Analogs
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
Somatostatin analogs (e.g., octreotide) directly inhibit the release of growth hormone, completely counteracting the intended therapeutic effect of Tesamorelin.
Actionable advice:
Avoid using these medications together as they have opposing pharmacological effects.
Target id:
/biomarker/igf-1
Target name:
Insulin-like Growth Factor 1 (IGF-1)
Severity:
major
Interaction type:
requirement
Nature:
absolute
Description:
Monitoring IGF-1 levels is essential to ensure the dose is effective but not causing supra-physiological levels, which are associated with long-term health risks.
Actionable advice:
Regularly test your IGF-1 levels at baseline and during treatment to guide dosing.
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
By increasing blood glucose, Tesamorelin may counteract the effects of diabetes medications, potentially requiring dose adjustments to maintain glycemic control.
Actionable advice:
Monitor blood glucose closely and consult your doctor, as your diabetes medication dosage may need to be increased.
Target id:
/class/corticosteroids
Target name:
Corticosteroids
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Tesamorelin-induced growth hormone can inhibit the enzyme (11β-HSD-1) that converts inactive cortisone to active cortisol, potentially reducing cortisol levels and requiring an increased dose of corticosteroids.
Actionable advice:
If you are on long-term corticosteroid therapy, your doctor may need to monitor you and adjust your dose.
Target id:
/class/cyp3a4-substrates
Target name:
CYP3A4 Substrates
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Growth hormone, which is increased by Tesamorelin, has been shown to inhibit CYP3A4 enzymes, potentially increasing the concentration and risk of side effects from drugs metabolized by this pathway.
Actionable advice:
Be aware of potential increased effects of other medications; consult a pharmacist or doctor about your specific drug regimen.
Target id:
/class/ghrps-ghrhs
Target name:
Other Growth Hormone Secretagogues
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Combining Tesamorelin with other peptides that stimulate growth hormone release (e.g., Ipamorelin, CJC-1295) can lead to an excessive and potentially unsafe increase in GH and IGF-1 levels.
Actionable advice:
Avoid co-administration with other GH-releasing peptides unless under expert medical guidance with frequent lab monitoring.
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Patients with kidney disease may have difficulty clearing the drug and are more susceptible to side effects like fluid retention and edema.
Actionable advice:
Use with caution and under medical supervision if you have kidney disease.
Target id:
/biomarker/hemoglobin-a1c
Target name:
Hemoglobin A1c
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Description:
Due to the risk of increased blood sugar and insulin resistance, monitoring long-term glucose control with HbA1c is a critical safety measure.
Actionable advice:
Test your HbA1c and fasting glucose before starting and periodically during treatment.
Target id:
/class/statins
Target name:
Statins
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Description:
Some statins (like simvastatin and atorvastatin) are metabolized by CYP3A4; Tesamorelin's induction of GH may slightly increase their blood levels, theoretically raising the risk of side effects like muscle pain.
Actionable advice:
Monitor for any new or worsening muscle pain or weakness while taking this combination.
Target id:
/condition/thyroid-disorders
Target name:
Thyroid Disorders
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Description:
Increased growth hormone can accelerate the conversion of T4 to T3, which may unmask or worsen central hypothyroidism. Thyroid function should be monitored.
Actionable advice:
Ensure your thyroid function is monitored periodically by your doctor while on therapy.